内容紹介
Risk Factors for Cardiotoxicity During Fluorouracil and Cisplatin Combination Chemotherapy
Summary
We investigated the incidence of cardiovascular symptoms in patients treated with fluorouracil and cisplatin (FP) combination chemotherapy. Between April 2010 and March 2011, 61 patients were treated with FP therapy at the Department of Gastroenterology, Niigata Prefectural Cancer Center Hospital. Within 1 week of treatment and within the first or second course of therapy, six patients developed chest pain. To investigate the risk factors for cardiotoxicity following FP therapy, patients were divided into cardiotoxicity incidence and non-incidence groups. The prevalence of diabetes, hypertension, and heart disease was not significantly different between the two groups. Furthermore, serum sodium and potassium levels were not altered following FP therapy. Therefore, no definitive risk factors for cardiotoxicity were identified. These results suggest that while FP chemotherapy-induced nausea, vomiting, and renal damage are serious adverse effects, further attention should also be paid to the potential cardiotoxic effects of FP therapy.
要旨
新潟県立がんセンター新潟病院消化器内科において,フルオロウラシルとシスプラチンの併用化学療法(FP療法)を施行した食道癌患者を対象に,循環器系副作用の発現状況を調査しリスク因子を検討した。調査期間中61例にFP療法が実施され,そのうち6例に胸痛,胸部不快感など循環器系副作用が発生した。全例,コース開始1週間以内に発生した。循環器系疾患の危険因子である高血圧,糖尿病など患者背景に差は認められず,FP療法実施前・後の電解質の変化と循環器系副作用との明らかな関連性は認められなかった。FP療法の副作用として悪心・嘔吐,骨髄抑制,腎障害などの副作用は広く認識されており,その対策は周知されているが,循環器系に対する副作用についても十分な注意が必要である。
目次
Summary
We investigated the incidence of cardiovascular symptoms in patients treated with fluorouracil and cisplatin (FP) combination chemotherapy. Between April 2010 and March 2011, 61 patients were treated with FP therapy at the Department of Gastroenterology, Niigata Prefectural Cancer Center Hospital. Within 1 week of treatment and within the first or second course of therapy, six patients developed chest pain. To investigate the risk factors for cardiotoxicity following FP therapy, patients were divided into cardiotoxicity incidence and non-incidence groups. The prevalence of diabetes, hypertension, and heart disease was not significantly different between the two groups. Furthermore, serum sodium and potassium levels were not altered following FP therapy. Therefore, no definitive risk factors for cardiotoxicity were identified. These results suggest that while FP chemotherapy-induced nausea, vomiting, and renal damage are serious adverse effects, further attention should also be paid to the potential cardiotoxic effects of FP therapy.
要旨
新潟県立がんセンター新潟病院消化器内科において,フルオロウラシルとシスプラチンの併用化学療法(FP療法)を施行した食道癌患者を対象に,循環器系副作用の発現状況を調査しリスク因子を検討した。調査期間中61例にFP療法が実施され,そのうち6例に胸痛,胸部不快感など循環器系副作用が発生した。全例,コース開始1週間以内に発生した。循環器系疾患の危険因子である高血圧,糖尿病など患者背景に差は認められず,FP療法実施前・後の電解質の変化と循環器系副作用との明らかな関連性は認められなかった。FP療法の副作用として悪心・嘔吐,骨髄抑制,腎障害などの副作用は広く認識されており,その対策は周知されているが,循環器系に対する副作用についても十分な注意が必要である。